Holen Sie sich die Stockscreener-App
1.79
2.29%
0.04
Schlusskurs vom Vortag:
$1.75
Offen:
$1.75
24-Stunden-Volumen:
3.74M
Relative Volume:
6.66
Marktkapitalisierung:
$95.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-78.34M
KGV:
-1.2079
EPS:
-1.4819
Netto-Cashflow:
$-75.02M
1W Leistung:
+34.59%
1M Leistung:
+42.06%
6M Leistung:
+33.58%
1J Leistung:
+29.71%
1-Tages-Spanne:
$1.68
$1.87
1-Wochen-Bereich:
$1.30
$1.91
52-Wochen-Spanne:
$1.02
$1.91
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Firmenname
Pmv Pharmaceuticals Inc
Sektor
Branche
Telefon
(609) 642-6670
Adresse
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.79 | 71.10M | 0 | -78.34M | -75.02M | -1.4819 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-05-13 | Eingeleitet | Craig Hallum | Buy |
| 2024-04-12 | Eingeleitet | Jefferies | Buy |
| 2023-12-27 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-09-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-19 | Eingeleitet | Oppenheimer | Perform |
| 2021-08-02 | Eingeleitet | Guggenheim | Buy |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Cowen | Outperform |
| 2020-10-20 | Eingeleitet | Evercore ISI | Outperform |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Pmv Pharmaceuticals Inc Aktie (PMVP) Neueste Nachrichten
Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca
These Biotech Stocks Are Cheap Based On 1 Fundamental Measure - Yahoo Finance
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross? - Zacks Investment Research
An investor group in PMV Pharmaceuticals (NASDAQ: PMVP) is held just under a 10% stake by its warrant terms. - Stock Titan
PMV Pharmaceuticals, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (PMVP) - Traders Union
PMV Pharmaceuticals, Inc. (PMVP) Earnings Date, Reports and Estimates - Traders Union
PMV Pharma appoints Philip Herman as CCO - thepharmaletter.com
symbol__ Stock Quote Price and Forecast - cnn.com
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - Yahoo Finance
PMVP SEC Filings, Jul-Aug 2025PMV Pharmaceuticals, Inc. Filing Archive - Stock Titan
PMV Pharmaceuticals stock gains as biotech peers advance - ad-hoc-news.de
PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target - AD HOC NEWS
PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering - TipRanks
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance
PMV Pharmaceuticals (PMVP) Announces $50.8M Oversubscribed Offering Amid Mixed Market Signals - GuruFocus
Oppenheimer Initiates PMV Pharmaceuticals(PMVP.US) With Buy Rating, Announces Target Price $5 - Moomoo
PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals (PMVP) Updates Interim Ovarian Cancer Trial Results Amid Valuation Challenges - GuruFocus
PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data - TipRanks
PMV Pharmaceuticals reports 46% ORR in ovarian cohort, plans NDA filing in Q1 2027 - TradingView
PMV Pharma Announces Proposed Public Offering of Securities - GlobeNewswire
PMV Pharmaceuticals, Inc. Announces Updated Interim Ovarian Cancer Data for Rezatapopt Monotherapy From PYNNACLE Phase 2 Pivotal Trial - marketscreener.com
Ovarian cancer trial reports a 46% response rate; FDA filing planned - Stock Titan
PMVP Q1 2026 Earnings: Narrower-than-Expected Loss of -$0.34 Reflects Cost DisciplineEnergy Earnings Report - dars.gov.et
ETFs Investing in PMV Pharmaceuticals, Inc. Stocks - TradingView
PMV (PMVP) Watch: Moves 1.15% Higher to $1.31; Price Context: Price Remains Between $1.24 Support and $1.38 Resistance in the Latest SessionValue Factor - vinanet.vn
PMV (PMVP) Latest Quarter: The Available Earnings Metric Delivers a Beat in the Latest Reading; Closing Move: The Stock Records a 3.23% Increase on the DayAnalyst Coverage Count - vinanet.vn
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
PMV Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Canada
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
PMV Pharma Reports $18.1 Million Second-Quarter Net Loss - Quiver Quantitative
PMV Pharmaceuticals (PMVP) flags going-concern risk as rezatapopt advances toward NDA - Stock Titan
PMVP: Net loss narrowed, but liquidity concerns persist as rezatapopt advances toward NDA submission - TradingView
Press Release: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - Moomoo
PMV Pharmaceuticals Inc (PMVP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PMV Pharmaceuticals Inc (PMVP) Stock News Today - TradingKey
PMVP Q2'26 Earnings: EPS estimate is (0.39) USD - TradingView
PMV Pharmaceuticals Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
PMV Pharmaceuticals (PMVP) Projected to Announce Earnings on Thursday - MarketBeat
PMV Pharmaceuticals Inc (PMVP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sio Capital discloses 4.94% PMV Pharmaceuticals (PMVP) stake below 5% threshold - stocktitan.net
PMV Pharmaceuticals Inc (PMVP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PMV Pharmaceuticals Inc (PMVP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PMV Pharmaceuticals Inc (PMVP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PMV Pharmaceuticals Inc (PMVP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Finanzdaten der Pmv Pharmaceuticals Inc-Aktie (PMVP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pmv Pharmaceuticals Inc-Aktie (PMVP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Oct 23 '25 |
Sale |
1.52 |
1,000,000 |
1,520,000 |
4,975,291 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):